2023
Vascular-Targeted Therapy for Systemic Lupus Erythematosus–Associated Vasculitis
Xu S, Patrignelli R, Ramachandran S, Koumpouras F, Desir D, Ko C, Gehlhausen J. Vascular-Targeted Therapy for Systemic Lupus Erythematosus–Associated Vasculitis. JAMA Dermatology 2023, 159: 460-462. PMID: 36884229, DOI: 10.1001/jamadermatol.2023.0077.Peer-Reviewed Original Research
2021
Chapter 11 Interferons and cytokines in SLE pathogenesis and therapy
Koumpouras F, Bucala R. Chapter 11 Interferons and cytokines in SLE pathogenesis and therapy. 2021, 169-180. DOI: 10.1016/b978-0-12-820583-9.00015-4.Peer-Reviewed Original Research
2019
FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Merrill J, June J, Koumpouras F, Machua W, Khan M, Askanase A, Khosroshahi A, Sheikh S, James J, Guthridge J, Rathi G, Burington B, Foster P, Zack D. FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). 2019, 761.2-762. DOI: 10.1136/annrheumdis-2019-eular.4234.Peer-Reviewed Original Research98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE)
Merrill J, June J, Koumpouras F, Machua W, Khan M, Askanase A, Sheikh S, Khosroshahi A, Foster P, Zack D. 98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE). 2019, a73-a74. DOI: 10.1136/lupus-2019-lsm.98.Peer-Reviewed Original Research